The development of small-molecule inhibitors of SIRT1 for the treatment of cancer is under consideration, and activation of SIRT1 alone was suggested as sufficient to induce tumor suppression in human cancers with mutated p53 [76-78]. This evidence concerns the gene TP53 and cancer.